Link Cell Therapies
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $60M
Overview
Developer of off-the-shelf, engineered allogeneic cell therapies for cancer and autoimmune disorders.
OncologyImmunologyCell Therapy
Technology Platform
A gene-editing platform for creating allogeneic cell therapies with edits to prevent rejection and enhance anti-tumor or immunomodulatory activity.
Funding History
1Total raised:$60M
Seed$60M
Opportunities
Tapping into the large market for more accessible and potent cell therapies beyond the current autologous standard.
Risk Factors
Clinical risks of allogeneic cell persistence, potential for GvHD or host rejection, and intense competition.
Competitive Landscape
Competes with numerous well-funded biotechs and large pharma in the rapidly advancing allogeneic cell therapy arena.